Peter Greenleaf
2020 - Aurinia Pharmaceuticals
In 2020, Peter Greenleaf earned a total compensation of $10.7M as Chief Executive Officer at Aurinia Pharmaceuticals, a 104% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $707,070 |
|---|---|
| Option Awards | $7,753,906 |
| Salary | $673,400 |
| Stock Awards | $1,534,992 |
| Other | $9,500 |
| Total | $10,678,868 |
Greenleaf received $7.8M in option awards, accounting for 73% of the total pay in 2020.
Greenleaf also received $707.1K in non-equity incentive plan, $673.4K in salary, $1.5M in stock awards and $9.5K in other compensation.
Rankings
In 2020, Peter Greenleaf's compensation ranked 754th out of 13,090 executives tracked by ExecPay. In other words, Greenleaf earned more than 94.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 754 out of 13,090 | 94th |
Division Manufacturing | 261 out of 5,618 | 95th |
Major group Chemicals And Allied Products | 83 out of 2,251 | 96th |
Industry group Drugs | 72 out of 1,951 | 96th |
Industry Pharmaceutical Preparations | 55 out of 1,456 | 96th |
Source: SEC filing on May 10, 2021.
Greenleaf's colleagues
We found five more compensation records of executives who worked with Peter Greenleaf at Aurinia Pharmaceuticals in 2020.
2020
Max Colao
Aurinia Pharmaceuticals
Chief Commercial Officer
2020
Joe Miller
Aurinia Pharmaceuticals
Chief Financial Officer
2020
Stephen Robertson
Aurinia Pharmaceuticals
General Counsel
2020
Max Donley
Aurinia Pharmaceuticals
EVP, Operations and Strategy
2020
Dennis Bourgeault
Aurinia Pharmaceuticals
Chief Financial Officer
News
Aurinia Pharmaceuticals CEO Peter Greenleaf's 2021 pay falls 88% to $1.2M
April 18, 2022
Aurinia Pharmaceuticals CEO Peter Greenleaf's 2020 pay jumps 1,353% to $11M
May 10, 2021
Avalo Therapeutics Chairman Simon Pedder's 2019 pay jumps 13,562% to $3.8M
April 28, 2020
Avalo Therapeutics CEO Peter Greenleaf's 2018 pay jumps 17,372% to $5.1M
June 19, 2019